HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
about
The effect of sexually transmitted co-infections on HIV viral load amongst individuals on antiretroviral therapy: a systematic review and meta-analysis.Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.Pharmacokinetics of antiretrovirals in mucosal tissueRelationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data.Progesterone Levels Associate with a Novel Population of CCR5+CD38+ CD4 T Cells Resident in the Genital Mucosa with Lymphoid Trafficking Potential.Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study.Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy
P2860
Q35677880-B7ED7A66-025B-4D09-AE2F-B22A3AFA27ECQ35706140-8003E0C2-E24A-45F5-95E7-DEAD64F32861Q35838594-0178B037-DE55-4DF5-AA97-C30777195DCBQ36078470-AEF34D65-6321-438D-A7A5-754C9DAD763BQ36343568-14DBEFAD-9C23-4560-A737-1AE7C577FD2CQ37018399-13CBC7E5-8DE7-4EDD-8FDB-471B4F1A5BEAQ37705397-2F51B021-FFA8-4521-ACB8-8FDA2B37ED92Q40747185-FC4241D9-E10B-40B6-932A-98216647C376Q45326390-95623EF5-38F1-4598-8014-4D6774452CB7Q49926142-A023C50F-EE1B-4930-BEC0-FA2C3B43F606Q58855461-B1E77F61-25D4-4A70-9681-3AD6CEE15FCE
P2860
HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@ast
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@en
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@nl
type
label
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@ast
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@en
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@nl
prefLabel
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@ast
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@en
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@nl
P2093
P2860
P356
P1476
HIV-1 genital shedding is supp ...... hroughout the menstrual cycle.
@en
P2093
Amy Martin
Anandi N Sheth
Chelsea Gatcliffe
Cheng-Yen Chen
Chou-Pong Pau
Clyde Hart
Damien Danavall
Igho Ofotokun
L Davis Lupo
Michael W Omondi
P2860
P304
P356
10.1093/INFDIS/JIU166
P407
P577
2014-03-18T00:00:00Z